FOS and metabolic dysfunction-associated steatotic liver disease: Although it has been reported to be a biomarker for Alzheimer’s disease and type 2 diabetes, there are many studies that have explored the biomarker status of FOS in NAFLD, NASH, and even fatty liver disease.